BACKGROUND To evaluate visual outcomes following LASIK and Photorefractive Keratectomy (PRK) in low-to-moderate myopia and/or myopic astigmatism in age and refractive error matched eyes. MATERIALS AND METHODS Of a total 30 patients aged ≥21 years, 20 (40 eyes) underwent LASIK and 10 (20 eyes) underwent PRK for low-to-moderate myopia or myopic astigmatism. LASIK was performed with the Alcon wave light 500 and PRK with the alcohol application for epithelial removal. All ablations were performed using the same excimer laser system. One surgeon operated all patients by using an excimer laser (Alcon wave light 500 system). Age and refractive error matched patients were divided in two groups. Preoperative and one year postoperative uncorrected visual acuity, best corrected visual acuity and manifest refractions were recorded to compare the outcomes of both the procedures. Outcome measures to assess the patient comfort levels in both groups include postoperative pain and quality of vision. Other outcome measures to assess the wound healing includes intraoperative complications, corneal haze and corneal reepithelialisation. RESULTS Sixty eyes of 30 patients were found matched regarding age and refractive error. In PRK group, among 10 patients, 5 (50%) were males and 5 (50%) were females, whereas in Lasik group, males were 12 (60%) and 8 (40%) were female patients. Mean preoperative MRSE was-4.06 ± 1.00 Dioptres (D) for LASIK versus-4.50 ± 1.25 D for PRK. Complete flap healing was achieved by postoperative day 4 in 86.9% of LASIK eyes versus complete reepithelialisation in 92.4% of PRK eyes. Using Fisher exact test, a significantly higher percentage of LASIK eyes compared to PRK eyes achieved 20/15 or better at 1 month (35.8% vs. 17.8%, P=0.031), 3 months (69.3% vs. 49.3%, P=0.004), 6 months (79.1% vs. 59.9%, P<0.001) and 12 months (85.9% vs. 61.9%, P=0.002). A change in MRSE >0.50 D occurred in 12.4% of LASIK eyes within the 3-and 12-month interval versus 25.7% of PRK eyes (P=0.04). Patients in both groups were happy regarding their visual outcome. CONCLUSION LASIK showed superior refractive efficacy and stability for low-to-moderate myopia with RBT (residual bed thickness) >320 microns. PRK shows better results in thinner corneas (RBT 280-320 microns). Both treatments were safe and comparable except in terms of pain and haze formation in selective PRK cases.
BACKGROUND The aim of this study was to determine the efficacy of toric IOL placement in astigmatic patients with immature cataract. MATERIALS AND METHODS This prospective study included 20 eyes of 20 patients with a visually significant cataract and corneal astigmatism ≥1.00 D. All patients underwent phacoemulsification and implantation of SP TORIC IOL. The unaided visual acuity and best corrected visual acuity were evaluated. Toric IOL axis and alignment was measured with slit lamp examination. The IOL manufacturer's webbased toric calculator was used to determine the required cylinder power and axis for the IOL that was going to be implanted. RESULTS Post-operative examination was conducted at day 1, day 3, after 1st week, and 1 month later. The average cylinder in IOL plane is 3.04D±0.66SD. and average cylinder in corneal plane is 2.14D±0.38. The average pre op LOG MAR was 0.8±0.2SD. One month postoperatively, the average Log MAR is 0.2±0.21SD. And the difference LOG MAR is 0.61±0.31SD. Inference: A significant improvement was noted after surgery in Log MAR values. Among 20 patients, 18 (90%) patients had improved visual acuity, 2 (10%) patients didn't show any visual improvement due to misalignment of IOL axis. There were no significant intraoperative complications among the study population. CONCLUSION Implantation of SPTORIC IOL is an effective and safe method to correct corneal astigmatism during cataract surgery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.